



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am on Tuesday 20th April 2021
(via Zoom)**

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/0421
5. **Chairman's report**
6. **AWTTC Work Programme:**
 - **AWTTC Work Programme update** 2/AWMSG/0421
(responses to consultation for information/comment)
 - **AWTTC Medicines Optimisation Framework** (for endorsement) 3/AWMSG/0421
 - **NHS Wales GP Cluster Prescribing Leads Forum proposal** 4/AWMSG/0421
(for information/comment)
 - **AWTTC: Supporting implementation of ATMPs in NHS Wales** 5/AWMSG/0421
(for information/comment)
7. **Feedback from the All Wales Prescribing Advisory Group meeting held 17th March 2021** 6/AWMSG/0421
8. **Appraisal 1: Limited Submission** 7/AWMSG/0421
buprenorphine/naloxone (Suboxone[®]) for the treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction
Appendices

The outcome of the appraisal will be uploaded to the AWMSG website after the meeting. The applicant company will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AWTTC. AWMSG's recommendation will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant company or after the ten-day deadline has expired – whichever is sooner. Welsh Government takes account of the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.